| Eye Care For Rhode Island | |
|
939 W Main Rd, Middletown, RI 02842-6390 | |
| (401) 847-1383 | |
| (401) 847-1384 |
| Full Name | Eye Care For Rhode Island |
|---|---|
| Type | Facility |
| Speciality | Ophthalmology |
| Location | 939 W Main Rd, Middletown, Rhode Island |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851492482 | NPI | - | NPPES |
| 0017102 | Other | MA | MEDICARE |
| CC41177 | Medicaid | RI | |
| 9022363 | Medicaid | RI | |
| 9004227 | Medicaid | RI | |
| 709006179 | Other | RI | MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Secondary |
| 207W00000X | Ophthalmology | (* (Not Available)) | Primary |
| Provider Name | Charles M Collins |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1457452120 PECOS PAC ID: 0042209710 Enrollment ID: I20040507001179 |
News Archive
Less than a decade ago, the Food and Drug Administration approved drugs for treating type 2 diabetes in an entirely new way.
Seven years after tobacco companies signed the Master Settlement Agreement prohibiting them from paying for tobacco brand appearances in movies, the number of tobacco brand appearances in PG-13 rated movies has not experienced a statistically significant decrease, according to a study by Dartmouth Medical School researchers.
CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the closing of a $70 million Series D financing round. The financing was led by Fidelity Management & Research Company with participation from Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners, Wellington Management Company and additional undisclosed investors.
American researchers are suggesting that adults who suffer from psoriasis are at an increased risk of a heart attack.
› Verified 1 days ago
| Provider Name | Frederic Kelley |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1659472249 PECOS PAC ID: 0143252981 Enrollment ID: I20050901000340 |
News Archive
Less than a decade ago, the Food and Drug Administration approved drugs for treating type 2 diabetes in an entirely new way.
Seven years after tobacco companies signed the Master Settlement Agreement prohibiting them from paying for tobacco brand appearances in movies, the number of tobacco brand appearances in PG-13 rated movies has not experienced a statistically significant decrease, according to a study by Dartmouth Medical School researchers.
CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the closing of a $70 million Series D financing round. The financing was led by Fidelity Management & Research Company with participation from Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners, Wellington Management Company and additional undisclosed investors.
American researchers are suggesting that adults who suffer from psoriasis are at an increased risk of a heart attack.
› Verified 1 days ago
| Provider Name | Carlos R Defreitas |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1336136894 PECOS PAC ID: 0446385264 Enrollment ID: I20100323000262 |
News Archive
Less than a decade ago, the Food and Drug Administration approved drugs for treating type 2 diabetes in an entirely new way.
Seven years after tobacco companies signed the Master Settlement Agreement prohibiting them from paying for tobacco brand appearances in movies, the number of tobacco brand appearances in PG-13 rated movies has not experienced a statistically significant decrease, according to a study by Dartmouth Medical School researchers.
CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the closing of a $70 million Series D financing round. The financing was led by Fidelity Management & Research Company with participation from Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners, Wellington Management Company and additional undisclosed investors.
American researchers are suggesting that adults who suffer from psoriasis are at an increased risk of a heart attack.
› Verified 1 days ago
| Provider Name | Lucas James Medeiros |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1649967498 PECOS PAC ID: 8426403213 Enrollment ID: I20231013003276 |
News Archive
Less than a decade ago, the Food and Drug Administration approved drugs for treating type 2 diabetes in an entirely new way.
Seven years after tobacco companies signed the Master Settlement Agreement prohibiting them from paying for tobacco brand appearances in movies, the number of tobacco brand appearances in PG-13 rated movies has not experienced a statistically significant decrease, according to a study by Dartmouth Medical School researchers.
CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the closing of a $70 million Series D financing round. The financing was led by Fidelity Management & Research Company with participation from Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners, Wellington Management Company and additional undisclosed investors.
American researchers are suggesting that adults who suffer from psoriasis are at an increased risk of a heart attack.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eye Care For Rhode Island 939 W Main Rd, Middletown, RI 02842-6390 Ph: (401) 847-1383 | Eye Care For Rhode Island 939 W Main Rd, Middletown, RI 02842-6390 Ph: (401) 847-1383 |
News Archive
Less than a decade ago, the Food and Drug Administration approved drugs for treating type 2 diabetes in an entirely new way.
Seven years after tobacco companies signed the Master Settlement Agreement prohibiting them from paying for tobacco brand appearances in movies, the number of tobacco brand appearances in PG-13 rated movies has not experienced a statistically significant decrease, according to a study by Dartmouth Medical School researchers.
CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the closing of a $70 million Series D financing round. The financing was led by Fidelity Management & Research Company with participation from Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners, Wellington Management Company and additional undisclosed investors.
American researchers are suggesting that adults who suffer from psoriasis are at an increased risk of a heart attack.
› Verified 1 days ago